Klein, M., Sriramoju, V. B., Cervantes, A., Varunok, N., Madan, S., Weck, K., … Stouffer, G. (2018). THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY. Journal of the American College of Cardiology, 71(11), A1196–A1196. https://doi.org/10.1016/s0735-1097(18)31737-6

Klein, Melissa, Vindhya B. Sriramoju, Alexandra Cervantes, Nicholas Varunok, Shivanshu Madan, Karen Weck, Craig Lee, and George Stouffer. “THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY.” Journal of the American College of Cardiology 71, no. 11 (March 2018): A1196–A1196. https://doi.org/10.1016/s0735-1097(18)31737-6.

Klein M, Sriramoju VB, Cervantes A, Varunok N, Madan S, Weck K, et al. THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY. Journal of the American College of Cardiology. 2018 Mar;71(11):A1196–A1196.

Klein, Melissa, et al. “THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY.” Journal of the American College of Cardiology, vol. 71, no. 11, Elsevier BV, Mar. 2018, pp. A1196–A1196. Crossref, doi:10.1016/s0735-1097(18)31737-6.

Klein M, Sriramoju VB, Cervantes A, Varunok N, Madan S, Weck K, Lee C, Stouffer G. THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY. Journal of the American College of Cardiology. Elsevier BV; 2018 Mar;71(11):A1196–A1196.